Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
최신 재무제표(Form-10K)에 따르면, Sol Gel Technologies Ltd의 총 자산은 $35이며, 순손실입니다.
SLGL의 주요 재무 비율은 무엇인가요?
Sol Gel Technologies Ltd의 유동비율은 5.83이고, 순이익률은 -90.9, 주당 매출은 $3.94입니다.
Sol Gel Technologies Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Sol Gel Technologies Ltd 주요 수익원은 Topical Dermatological Drug이며, 최신 수익 발표에서 수익은 1,554,000입니다. 지역별로는 Israel이 Sol Gel Technologies Ltd의 주요 시장이며, 수익은 1,554,000입니다.
Sol Gel Technologies Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 Sol Gel Technologies Ltd의 순손실은 $-10입니다.